Find new targets. Predict the best patients. And know how well new drugs will work, before they’re tested in humans. Applying transomic technology that uses functional data, Pepper develops treatments for diseases once thought to be untreatable — until now.
The Pepper platform drives more informed drug discovery and development, enabling us to create our own cures for highly aggressive cancers. See how our new techbio approach combines technology and biology to empower a new age of patient health.
Pepper has produced concrete results: proofs of concept across three therapeutic areas powering better drug discovery.
Pepper has produced concrete results: proofs of concept across three therapeutic areas powering better drug discovery.
Currently working with a paid industry partner on a drug mechanism of action study.
Publication pending
Pre-clinical discovery in untreatable cancers to create a proprietary disease database using transomic data.
Pre-clinical validation with an industry partner for indication expansion into IBD from RA.
Currently working with a paid industry partner on a drug mechanism of action study.
Publication pending
Pre-clinical validation with an industry partner for indication expansion into IBD from RA.
Pre-clinical discovery in untreatable cancers to create a proprietary disease database using transomic data.
Capture the full picture of disease biology and drug mechanism with global omic data.
See the reality of biological processes thanks to proteomic and phosphoproteomic data.
Understand actual drivers — not just correlation — with Pepper’s integrated analysis.
Our platform is the first to use a truly transomic analysis — integrating phosphoproteomics, proteomics, transcriptomics, and genomics. This whole-stack solution to common drug discovery challenges reveals actionable insights others miss.
Capture the full picture of disease biology and drug mechanism with global omic data.
See the reality of biological processes thanks to proteomic and phosphoproteomic data.
Our platform is the first to use a truly transomic analysis — integrating phosphoproteomics, proteomics, transcriptomics, and genomics. This whole-stack solution to common drug discovery challenges reveals actionable insights others miss.
Novel drug development
End-to-end drug discovery
Repeatable development process
Pepper enables faster, more precise drug development with technology that better informs almost every stage of the process. Our platform identifies new, previously missed insights to power novel drug programs — including four in current development.
Biomarker identification
Target identification
Indication expansion
Drug combinations
Patient stratification
Lead optimization
Pepper’s solutions identify new possibilities for advancing your business. We partner with your R&D teams, showing you where to start — and just how far you can go. It’s an engine for reliable, repeatable commercial success.
Novel drug development
End-to-end drug discovery
Repeatable development process
Pepper enables faster, more precise drug development with technology that better informs almost every stage of the process. Our platform identifies new, previously missed insights to power novel drug programs — including four in current development.
Drug combinations
Target identification
Patient stratification
Indication expansion
Lead optimization
Pepper’s solutions identify new possibilities for advancing your business. We partner with your R&D teams, showing you where to start — and just how far you can go. It’s an engine for reliable, repeatable commercial success.
CSO & Co-Founder
PhD, MIT
Samantha develops Pepper’s technology. An NSF Graduate Research Fellow, Churchill Scholar, and Goldwater Scholar, she pioneered omics analysis approaches in Electrical Engineering and Computer Science as well as Biological Engineering at MIT, mentored by Douglas Lauffenburger.
CEO & Co-Founder
MBA, Harvard Business School
Head, Biology
PhD, Newcastle University
Head, Business Development
PhD, Brown University
Senior Computational Biologist
PhD, University of California San Diego
Samuel leads Pepper’s data analysis and interpretation. He was previously a computational biologist at Fulcrum Therapeutics and completed his PhD in Bioinformatics and Systems Biology under Chris Benner at UCSD.
Chief Development Officer
PhD, University of Warwick
An experienced drug hunter with 4 approved drugs, Simon leads Pepper's pipeline development. His 25+ years of industry experience has taken him from a founding member of AnorMED, a startup acquired by Genzyme, to large pharma, Sanofi.
CSO & Co-Founder
PhD, MIT
Samantha develops Pepper’s technology. An NSF Graduate Research Fellow, Churchill Scholar, and Goldwater Scholar, she pioneered omics analysis approaches in Electrical Engineering and Computer Science as well as Biological Engineering at MIT, mentored by Douglas Lauffenburger.
CEO & Co-Founder
MBA, Harvard Business School
Head, Biology
PhD, Newcastle University
Head, Business Development
PhD, Brown University
Senior Platform Engineer
BS, University of Illinois Urbana-Champaign
Aru leads development of Pepper’s platform. Before joining Pepper, he worked as an organism engineer and computational biologist at Ginkgo Bioworks.
Chief Development Officer
PhD, University of Warwick
An experienced drug hunter with 3 approved drugs, Simon leads Pepper's pipeline development. His 25+ years of industry experience has taken him from a founding member of AnorMED, a startup acquired by Genzyme, to large pharma, Sanofi.
Senior Computational Biologist
PhD, University of California San Diego
Samuel leads Pepper’s data analysis and interpretation. He was previously a computational biologist at Fulcrum Therapeutics and completed his PhD in Bioinformatics and Systems Biology under Chris Benner at UCSD.
Contact us to learn how you can work with Pepper. Send us a message, and a member of our team will reach out to you shortly.
Click here to browse career opportunities at Pepper.
